Global API sourcing simplified
We connect API buyers and suppliers worldwide with speed, trust, and full transparency.

Filters

Filters
Filter
Custom request?
Type
Production region
Qualifications
Show more
Country of origin

Sarafloxacin API Manufacturers & Suppliers

1 verified results
Get full market intelligence report
Get full market intelligence report
Full access. Full negotiation power All Sarafloxacin data. Full access. Full negotiation power

Commercial-scale Suppliers

Producer
Produced in  China
|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: coa

All certificates

coa
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.
Get full market intelligence report
Get full market intelligence report
€399,-
All Sarafloxacin data. Full access. Full negotiation power
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency Total market transparency
|
Supplier trade data access Supplier trade data access
|
Buyer / supplier flow comparison Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Procaps
Pfizer
Reckitt
Sanofi
Blau
Abbvie

Sarafloxacin | CAS No: 98105-99-8 | GMP-certified suppliers

A medication that offers broad-spectrum antibacterial activity primarily for veterinary use, with CYP1A2 inhibition and potential QTc-prolonging risks requiring careful handling and quality control.

Therapeutic categories

Anti-Bacterial AgentsCytochrome P-450 CYP1A2 InhibitorsCytochrome P-450 CYP1A2 Inhibitors (strength unknown)Cytochrome P-450 Enzyme InhibitorsFluoroquinolonesHeterocyclic Compounds, Fused-Ring
Generic name
Sarafloxacin
Molecule type
small molecule
CAS number
98105-99-8
DrugBank ID
DB11491
Approval status
Vet_approved drug, Withdrawn drug

Product Snapshot

  • Sarafloxacin is an oral small molecule antibiotic formulation
  • It is primarily used for veterinary bacterial infections
  • The product has veterinary approval but has been withdrawn from the market

Clinical Overview

Sarafloxacin (CAS Number 98105-99-8) is a member of the fluoroquinolone class of antibiotics, characterized chemically as a phenylquinoline derivative. This class features a heterocyclic quinoline core with a phenyl substitution, contributing to its antimicrobial activity. Sarafloxacin was developed primarily for veterinary use but was discontinued by its manufacturer, Abbott Laboratories, before gaining regulatory approval for human use in the United States or Canada.

Although specific clinical indications for sarafloxacin are not documented in human medicine, its classification as a fluoroquinolone suggests activity against a broad spectrum of Gram-negative and some Gram-positive bacteria, consistent with this antibiotic class. Fluoroquinolones generally exert bactericidal effects by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes, essential for DNA replication and transcription. However, explicit pharmacodynamics and mechanism of action data for sarafloxacin are not publicly available.

Pharmacokinetic and ADME details specific to sarafloxacin are limited; fluoroquinolones are typically well absorbed orally, distribute extensively in tissues, and are cleared renally and hepatically. Sarafloxacin is identified as an inhibitor of cytochrome P450 enzyme CYP1A2, which may bear relevance in drug-drug interactions and metabolic considerations. It is also categorized among potential QTc-prolonging agents, implying a need for caution regarding cardiac safety, although clinical data on this is lacking.

Safety and toxicity profiles for sarafloxacin have not been extensively reported. Given its veterinary approval status and subsequent withdrawal, careful evaluation would be required before considering human therapeutic applications. Usage contexts today are primarily limited by its market withdrawal and lack of approval.

From an API sourcing perspective, strict quality controls are essential due to its fluoroquinolone structure and enzymatic inhibition characteristics. Procurement should ensure compliance with relevant pharmacopoeial standards and regulatory guidelines, particularly considering the compound’s withdrawn status and potential safety concerns.

Identification & chemistry

Generic name Sarafloxacin
Molecule type Small molecule
CAS 98105-99-8
UNII RC3WJ907XY
DrugBank ID DB11491

Formulation & handling

  • Sarafloxacin is a small molecule suitable for oral formulation due to its low water solubility and moderate lipophilicity.
  • Handling requires consideration of its withdrawn status and potential regulatory restrictions for veterinary use.
  • Stability profiles should account for its solid state and potential sensitivity to environmental factors affecting phenylquinoline derivatives.

Regulatory status

Sarafloxacin is a type of Fluorides


Fluorides are a crucial subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a significant role in various medical formulations. These compounds contain fluorine atoms and are widely used in the pharmaceutical industry due to their unique properties and therapeutic benefits.

One of the primary applications of fluorides is their ability to enhance drug stability and bioavailability. Incorporating fluorine atoms into drug molecules can improve their metabolic stability, which helps prolong their half-life and efficacy. Furthermore, fluorides can enhance the lipophilicity of drugs, facilitating their absorption through biological membranes and increasing their bioavailability.

Fluorides are particularly valuable in drug discovery and development processes. Pharmaceutical researchers often utilize fluorine substitution techniques to optimize drug properties such as potency, selectivity, and metabolic stability. By selectively replacing hydrogen atoms with fluorine, medicinal chemists can modify the physicochemical and pharmacokinetic properties of drug molecules, leading to improved drug candidates with enhanced therapeutic potential.

Additionally, fluorides find extensive application in positron emission tomography (PET) imaging. Fluorine-18, a radioactive isotope of fluorine, can be incorporated into various molecules to create radiotracers. These radiotracers are used to visualize and monitor physiological processes in vivo, providing valuable diagnostic information in areas such as oncology, neurology, and cardiology.

In summary, fluorides represent a critical subcategory of pharmaceutical APIs with diverse applications in drug development and diagnostics. Their incorporation into drug molecules enhances stability, bioavailability, and therapeutic potential. By leveraging the unique properties of fluorides, pharmaceutical researchers can advance the development of innovative drugs and improve patient outcomes.


Sarafloxacin (Fluorides), classified under Therapeutic Nutrients/Minerals/Electrolyte


Therapeutic Nutrients/Minerals/Electrolytes: A Comprehensive Technical DescriptionTherapeutic nutrients, minerals, and electrolytes are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used to support and enhance overall health and well-being. These compounds play a crucial role in maintaining the body's physiological balance, aiding in various metabolic processes, and addressing specific deficiencies.

Therapeutic nutrients encompass a broad range of substances, including vitamins, minerals, and electrolytes. Vitamins are organic compounds required in small quantities for proper bodily functions and are essential for growth, development, and disease prevention. Minerals, on the other hand, are inorganic substances that support numerous physiological processes, such as bone formation, nerve function, and energy production.

Electrolytes are minerals that carry an electric charge when dissolved in bodily fluids, including sodium, potassium, calcium, magnesium, and chloride. They play a crucial role in maintaining proper hydration, nerve impulses, muscle contractions, and pH balance.

Pharmaceutical APIs in the Therapeutic Nutrients/Minerals/Electrolyte category are designed to address specific deficiencies or imbalances in the body. These APIs are often used in the formulation of dietary supplements, nutritional products, and therapeutic treatments. They are manufactured under stringent quality control guidelines to ensure purity, potency, and bioavailability.

Therapeutic nutrients/minerals/electrolytes APIs are available in various forms, including tablets, capsules, powders, and liquid formulations. They are formulated to meet specific dosage requirements and can be combined with other ingredients for targeted health benefits.

Overall, therapeutic nutrients, minerals, and electrolytes APIs are essential components in maintaining optimal health. Their use helps address deficiencies, support bodily functions, and promote overall well-being. Pharmaceutical companies and healthcare professionals rely on these high-quality APIs to develop effective and safe products that contribute to a healthier population.



Sarafloxacin API manufacturers & distributors

Compare qualified Sarafloxacin API suppliers worldwide. We currently have 1 companies offering Sarafloxacin API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.

SupplierTypeCountryProduct originCertificationsPortfolio
Producer
China China CoA5 products

When sending a request, specify which Sarafloxacin API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).

Use the list above to find high-quality Sarafloxacin API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.